- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02626364
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a proof of concept, single-arm study to investigate crenolanib monotherapy in patients with recurrent/refractory glioblastoma with PDGFRA gene amplification. Eligible patients include those with recurrent/refractory glioblastoma after prior therapy including surgery, radiation, and temozolomide. The trial is designed to assess the anti-tumor activity of crenolanib in recurrent/refractory glioblastoma with PDGFRA gene amplification based on the estimation of progression-free survival (PFS) at 6 months. Symptom burden will be evaluated using the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT).
Crenolanib will be administered orally continuously at 100 mg TID on a 28-day cycle basis . Patients are allowed to receive crenolanib for a maximum of 26 cycles if clinical benefit has been observed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 75243
- Md Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients (male or female) ≥ 18 years of age.
- Histopathologically confirmed glioblastoma or gliosarcoma (WHO Grade IV) confirmed by local pathology tissue screening.
- Radiologic evidence of first recurrence after initial treatment (including surgery, radiation, and temozolomide) or tumor refractory to initial treatment without subsequent treatment in glioblastoma or gliosarcoma (WHO Grade IV). Transformation from a lower grade glioma previously treated with radiation and/or temozolomide to glioblastoma will be considered first recurrence for the purpose of this trial
- Tumor tissue available from original diagnosis and/or recurrence; a minimum of 1 FFPE archival tumor tissue block (preferred) or a minimum of 20 FFPE unstained slides from initial and/or most recent pre-registration biopsy or resection. It is recommended that at least 1 cm^2 of tissue composed primarily (defined as greater than 85%) of tumor is present.
- Confirmed PDGFRA amplification in the tumor tissue at the time of diagnosis or time of recurrence. Central confirmation of PDGFRA amplification will be performed by FISH in CLIA certified lab (ProPath). Signal quantitation will be used to generate a PDGFRA/centromere 4 ratio. PDGFRA to Centromere 4 ratios will be interpreted as follows: 1.8 to 2.2, borderline for amplification; 2.2 to 5.0, low-level amplification; and greater than 5.0 or clustered signals that are too numerous to count would be considered highly amplified. Tumor samples with PDGFRA to Centromere 4 ratios of 2.2 or higher will be considered amplified and therefore eligible for this trial. For patients with local CLIA testing demonstrating PDGFRA amplification by Next Generation Sequencing (Foundation Medicine, CMS400), central testing will not be required.
Patients must have adequate organ function at baseline as defined below:
• Adequate liver function (within 7 days of crenolanib commencement), as determined by:
- Serum ALT, AST ≤ 2 × ULN
- Normal serum total bilirubin (lower and upper limits of local Laboratory)
- Adequate renal function assessed by: serum creatinine ≤ 1.5 × ULN
- KPS ≥ 60
- Recovered (returned to ≤ grade 1 as per CTCAE v4.03) from prior treatment-related toxicity.
- A minimum of 3 weeks must have elapsed from last intake of prior standard chemotherapy treatment.
- A minimum of 6 weeks must have elapsed from the last dose of nitrosoureas.
- A minimum of 5 half-lives of last dose of investigational agent must have elapsed prior to C1D1.
- More than 12 weeks from completion of chemoradiation, unless RANO criteria for early progression within 12 weeks of chemoradiation are met (See 18.1)
- Non-pregnant and non-nursing women of childbearing potential must have a negative serum or urine pregnancy test within 3 days of crenolanib commencement ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months).
- Women of childbearing potential and men must agree to use adequate contraception (simultaneous use of 2 methods of birth control) prior to study entry, for the duration of study participation and for 90 days following completion of therapy.
- Patient able and willing to provide informed consent.
- Ability to understand and willingness for follow-up visits.
Exclusion Criteria:
- Pre-existing liver diseases (i.e., cirrhosis, chronic hepatitis B or C, nonalcoholic steatohepatitis, and sclerosing cholangitis, etc.)
- Known positive for HIV
- Patients previously treated with bevacizumab.
- NYHA Class III-IV heart failure, myocardial infarction <6 months prior to study entry, and/or serious arrhythmia requiring anti-arrhythmic therapy
- Patients receiving concurrent anti-cancer treatment (chemotherapy, investigational agents, immunotherapy, endocrine therapy, or Optune®…)
- Patients with any other severe and/or uncontrolled concurrent disease affecting the cardiovascular system, liver, kidneys, hematopoietic system or else considered as clinically important by the investigator and that could be incompatible with patient's participation in this trial or would likely interfere with study procedures/results or compromise compliance with the protocol.
- Pregnant or breast-feeding women.
- Patients unable to swallow pills.
- Patients who are allergic to MRI contrast medium or unable to undergo MRI for any other reason.
- Patients unable to provide informed consent.
- Patients on EIADs are not eligible, unless the antiepileptic drug can be safely tapered and discontinued before C1D1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
crenolanib 100mg PO TID
|
single-agent crenolanib at 100 mg PO TID
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival at 6 months
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 3 years
|
3 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
Time Frame: 2 years
|
2 years
|
Overall response rate by RANO criteria
Time Frame: 1 year
|
1 year
|
Change in symptom burden using The MD Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT)
Time Frame: 2 years
|
2 years
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of response
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Barbara O'Brien, MD, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARO-015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent/Refractory Glioblastoma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Second Affiliated Hospital, School of Medicine,...Huizhou Municipal Central Hospital; BoYuan RunSheng Pharma (Hangzhou) Co.,... and other collaboratorsRecruitingRecurrent Glioblastoma | Refractory GlioblastomaChina
-
Second Affiliated Hospital, School of Medicine,...BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.UnknownRecurrent Glioblastoma | Refractory GlioblastomaChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Refractory GlioblastomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingMalignant Glioma | WHO Grade 3 Glioma | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Central Nervous System Neoplasm | Recurrent Brain Neoplasm | Recurrent Childhood...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...WithdrawnRecurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingOvarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditionsUnited States, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
Clinical Trials on crenolanib
-
Arog Pharmaceuticals, Inc.Terminated
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesUnited States
-
Arog Pharmaceuticals, Inc.AvailableFLT3-ITD Mutation | FLT3/TKD Mutation | PDGFR-Alpha D842V | PDGFRA Gene AmplificationItaly
-
Arog Pharmaceuticals, Inc.Centre Leon Berard; Fox Chase Cancer CenterUnknownGIST With D842V Mutated PDGFRA GeneUnited States, France, Spain, Italy, Germany, Norway, Poland
-
Arog Pharmaceuticals, Inc.CompletedD842-related Mutant GISTUnited States
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid LeukemiaUnited States
-
Arog Pharmaceuticals, Inc.CompletedPhase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating MutationsRelapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating MutationsUnited States
-
St. Jude Children's Research HospitalArog Pharmaceuticals, Inc.; The V Foundation for Cancer ResearchCompletedDiffuse Intrinsic Pontine Glioma | Progressive or Refractory High-Grade GliomaUnited States
-
Arog Pharmaceuticals, Inc.WithdrawnRelapsed/Refractory FLT3-mutated AML
-
Arog Pharmaceuticals, Inc.RecruitingNewly Diagnosed FLT3 Mutated AMLUnited States